AR066936A1 - 3 - (2R - TETRAHYDROFURIL - METHYL) - 2 - THIOXANTINE. PHARMACEUTICAL COMPOSITIONS. - Google Patents

3 - (2R - TETRAHYDROFURIL - METHYL) - 2 - THIOXANTINE. PHARMACEUTICAL COMPOSITIONS.

Info

Publication number
AR066936A1
AR066936A1 ARP080102458A ARP080102458A AR066936A1 AR 066936 A1 AR066936 A1 AR 066936A1 AR P080102458 A ARP080102458 A AR P080102458A AR P080102458 A ARP080102458 A AR P080102458A AR 066936 A1 AR066936 A1 AR 066936A1
Authority
AR
Argentina
Prior art keywords
methyl
tetrahydrofuryl
thioxanthin
thioxantine
tetrahydrofuril
Prior art date
Application number
ARP080102458A
Other languages
Spanish (es)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39744966&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR066936(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR066936A1 publication Critical patent/AR066936A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/22—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)

Abstract

Reivindicacion 1: La Forma A de 3-(2R-tetrahidrofuril-metil)-2-tioxantina. Reivindicacion 2: La Forma A de 3-(2R-tetrahidrofuril-metil)-2-tioxantina, caracterizada por proporcionar un patron de difraccion de rayos X de muestras en polvo que exhibe sustancialmente los siguientes valores de d: Reivindicacion 14: La forma B de 3-(2R-tetrahidrofuril-metil)-2-tioxantina segun la reivindicacion 13, caracterizada por valores °2theta de difraccion de rayos X de muestras en polvo de 16.56, 24.86 y 29.07 °2theta. Reivindicacion 26: El uso de una mezcla de 3-(2R-tetrahidrofuril-metil)-2-tioxantina segun cualquiera de las reivindicaciones 1-5 y de 3-(2R-tetrahidrofuril-metil)-2-tioxantina segun cualquiera de las reivindicaciones 11-15 como ingredientes activos en la fabricacion de un medicamento para su uso en el tratamiento o profilaxis de enfermedades o condiciones en las que la inhibicion de la enzima MPO es beneficiosa.Claim 1: Form A of 3- (2R-tetrahydrofuryl methyl) -2-thioxanthine. Claim 2: Form A of 3- (2R-tetrahydrofuryl-methyl) -2-thioxanthin, characterized by providing an X-ray diffraction pattern of powder samples that exhibits substantially the following values of d: Claim 14: Form B 3- (2R-tetrahydrofuryl-methyl) -2-thioxanthin according to claim 13, characterized by °2theta X-ray diffraction values of powder samples of 16.56, 24.86 and 29.07 ° 2theta. Claim 26: The use of a mixture of 3- (2R-tetrahydrofuryl-methyl) -2-thioxanthin according to any one of claims 1-5 and 3- (2R-tetrahydrofuryl-methyl) -2-thioxanthin according to any of the claims 11-15 as active ingredients in the manufacture of a medicament for use in the treatment or prophylaxis of diseases or conditions in which the inhibition of the MPO enzyme is beneficial.

ARP080102458A 2007-06-13 2008-06-09 3 - (2R - TETRAHYDROFURIL - METHYL) - 2 - THIOXANTINE. PHARMACEUTICAL COMPOSITIONS. AR066936A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US94367107P 2007-06-13 2007-06-13

Publications (1)

Publication Number Publication Date
AR066936A1 true AR066936A1 (en) 2009-09-23

Family

ID=39744966

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080102458A AR066936A1 (en) 2007-06-13 2008-06-09 3 - (2R - TETRAHYDROFURIL - METHYL) - 2 - THIOXANTINE. PHARMACEUTICAL COMPOSITIONS.

Country Status (19)

Country Link
US (1) US20080312311A1 (en)
EP (1) EP2158202A1 (en)
JP (1) JP2010529185A (en)
KR (1) KR20100020002A (en)
CN (1) CN101679435A (en)
AR (1) AR066936A1 (en)
AU (1) AU2008263582A1 (en)
BR (1) BRPI0812480A2 (en)
CA (1) CA2690468A1 (en)
CL (1) CL2008001766A1 (en)
CO (1) CO6251290A2 (en)
EC (1) ECSP109874A (en)
IL (1) IL202281A0 (en)
MX (1) MX2009013126A (en)
PE (1) PE20090367A1 (en)
RU (1) RU2010100484A (en)
TW (1) TW200916096A (en)
UY (1) UY31139A1 (en)
WO (1) WO2008152420A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR039385A1 (en) * 2002-04-19 2005-02-16 Astrazeneca Ab THIOXANTINE DERIVATIVES AS INHIBITORS OF MIELOPEROXIDASA
MY140748A (en) 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
US20090054468A1 (en) * 2007-08-23 2009-02-26 Astrazeneca Ab New Use 938
WO2010068171A1 (en) * 2008-12-12 2010-06-17 Astrazeneca Ab A process for the preparation of 3- [ (2r) tetrahydrofuran-2- ylmethyl] -2-thioxo-l, 2, 3, 7-tetrahydro-6h-purin-6-one
EA202090266A1 (en) * 2017-07-17 2020-06-05 Астразенека Аб MPO INHIBITORS FOR MEDICAL USE

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR039385A1 (en) * 2002-04-19 2005-02-16 Astrazeneca Ab THIOXANTINE DERIVATIVES AS INHIBITORS OF MIELOPEROXIDASA
SE0302756D0 (en) * 2003-10-17 2003-10-17 Astrazeneca Ab Novel Compounds
TW200806667A (en) * 2006-04-13 2008-02-01 Astrazeneca Ab New compounds
WO2007120097A1 (en) * 2006-04-13 2007-10-25 Astrazeneca Ab Thioxanthine derivatives and their use as inhibitors of mpo

Also Published As

Publication number Publication date
TW200916096A (en) 2009-04-16
US20080312311A1 (en) 2008-12-18
CN101679435A (en) 2010-03-24
CA2690468A1 (en) 2008-12-18
CL2008001766A1 (en) 2008-12-19
RU2010100484A (en) 2011-07-20
PE20090367A1 (en) 2009-04-15
CO6251290A2 (en) 2011-02-21
IL202281A0 (en) 2010-06-16
UY31139A1 (en) 2009-01-30
WO2008152420A1 (en) 2008-12-18
BRPI0812480A2 (en) 2017-05-23
AU2008263582A1 (en) 2008-12-18
MX2009013126A (en) 2010-01-15
JP2010529185A (en) 2010-08-26
KR20100020002A (en) 2010-02-19
ECSP109874A (en) 2010-02-26
EP2158202A1 (en) 2010-03-03

Similar Documents

Publication Publication Date Title
UY37461A (en) 1,2,4 - TRIAZOLONES 2,4,5 TRISUSTITUIDA
ECSP17007538A (en) 2- (MORFOLIN-4-IL) -1,7-NAPHTHYRIDINES
GT201400111A (en) SUBSTITUTED TRIAZOLOPIRIDINS
CR20140113A (en) IMIDAZOPIRIDAZINAS REPLACED WITH AMINO
CR10192A (en) AMIDO COMPOUNDS AND ITS USE AS PHARMACEUTICAL PRODUCTS
CR20140392A (en) SUBSTITUTED DIHYDROPIRAZOLONES
UY31228A1 (en) ARILOXAZOLES REPLACED AND ITS USE
GT200900230A (en) 4-ARIL-1,4-DIHIDRO-1,6-NAFTIRIDINAMIDES REPLACED AND USE
CO6410279A2 (en) PHARMACEUTICAL COMPOSITION THAT INCLUDES DERIVATIVES OF GLUCOPIRANOSIL DIFENYLMETHANE, PHARMACEUTICAL FORM OF THE SAME, PROCEDURE FOR THEIR PREPARATION AND USES OF THE SAME FOR IMPROVED GLUCEMIC CONTROL IN A PATIENT.
PA8772101A1 (en) IMIDAZOL-TRIAZOLOPIRIMIDINAS REPLACED
PA8660301A1 (en) PIRAZOLO PIRIDINAS REPLACED, COMPOSITIONS THAT CONTAIN THEM, MANUFACTURING AND USE PROCEDURE
AR058098A1 (en) DERIVATIVES OF DICARBOXYL ACIDS AND THEIR USE
UY35293A (en) ISOTIAZOLES REPLACED WITH AMINO
CL2010001348A1 (en) Compounds derived from 1-oxo-2,3-dihydro-1h-isoindolin-5-yl) -isoxazol-3-carboxamide, enhancers of mglur2; pharmaceutical composition; and its use to relieve symptoms or reduce the appearance of symptoms of ezchizophrenia or anxiety.
CO6690805A2 (en) 6-amino-nicotinamides substituted as modular of kcnq2 / 3
DOP2009000287A (en) OXAZOLIDINONES REPLACED AND ITS USE
ME01456B (en) Fumarate salt of (alpha s, beta r)-6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol
UY31133A1 (en) "SUBSTITUTED OXAZOLIDINONES AND ITS USE"
CU20120171A7 (en) SUBSTITUTED TRIAZOLOPIRIDINS
UY29343A1 (en) PIRAZOLOPIRIDINAS AND SALTS OF THE SAME, A PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS, A METHOD FOR PREPARING THEM AND THEIR USE.
CO6511222A2 (en) IDENONE DERIVATIVE AND FAMILY COMPOSITION THAT INCLUDES THE SAME
AR066936A1 (en) 3 - (2R - TETRAHYDROFURIL - METHYL) - 2 - THIOXANTINE. PHARMACEUTICAL COMPOSITIONS.
CL2011001829A1 (en) 3'-n-desmethyl-4 '' - o- (2-diethylaminoetanoyl) -6-o-methyl-9a-aza-9a-homoerythromycin a, its salts and crystalline forms 1, 2 and 3; Preparation process; use to treat inflammatory diseases; pharmaceutical composition; and composition which also comprises another active compound.
CU24011B1 (en) PIPERIDINS 2-PHENYL-5- (1,2,4-OXADIAZOL-5-IL) REPLACED
UY31143A1 (en) DERIVATIVES OF [1,10] -FENANTROLINE FOR THE TREATMENT OF NEURODEGENERATIVE OR HEMATOLOGICAL DISEASES

Legal Events

Date Code Title Description
FB Suspension of granting procedure